Illinois Tool Works Inc. (ITW) Pops 2.52% for February 12

Equities Staff |

One of the S&P 500’s big winners for Friday February 12 was Illinois Tool Works Inc. (ITW) as the company’s stock climbed 2.52% to $91.86 on volume of 997,761 shares.

The stock opened at $90.44 and saw an intraday low of $90.06 and an intraday high of $91.94. All told, the day saw a per-share gain of $2.255. The stock’s average daily volume of 1.87 million and 363.49 million shares outstanding. Illinois Tool Works Inc. now has a 50-day SMA is $89.10 and 200-day SMA is $89.07, and it has a 52-week high of $100.14 and a 52-week low of $78.79.

Illinois Tool Works Inc is a manufacturer of industrial products and equipment. Its segments are: Automotive OEM, Test and Measurement and Electronics, Food Equipment, Polymers and Fluids, Welding, Construction Products, and Specialty Products.

Based out of Glenview, IL, Illinois Tool Works Inc. has 49,000 employees and, after today’s trading, reached a market cap of $33.39 billion. The stock’s P/E Ratio is 17.5. Its P/S ratio is 2.43, P/B ratio is 6.57, and P/FCF ratio is 37.5.

For a complete fundamental analysis analysis of Illinois Tool Works Inc., check out’s Stock Valuation Analysis report for ITW. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…